IGI Logo

Biocon is currently trading at Rs. 270.20, up by 7.10 points or 2.70% from its previous closing of Rs. 263.10 on the BSE.

The scrip opened at Rs. 272.25 and has touched a high and low of Rs. 273.00 and Rs. 269.85 respectively. So far 38099 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 307.00 on 06-Feb-2024 and a 52 week low of Rs. 217.50 on 31-Oct-2023.

Last one week high and low of the scrip stood at Rs. 282.95 and Rs. 262.00 respectively. The current market cap of the company is Rs. 31587.79 crore.

The promoters holding in the company stood at 60.64%, while Institutions and Non-Institutions held 21.06% and 18.30% respectively.

Biocon has signed an exclusive licensing and supply agreement with Biomm S.A., a specialty pharmaceutical company in Brazil, for the commercialization of its vertically integrated drug product, Semaglutide (gOzempic), which is used to improve glycemic control in adults with type-2 diabetes. Under the terms of this agreement, Biocon will undertake the development, manufacturing and supply of the drug product, and Biomm will be responsible for obtaining regulatory approval and commercialization in the Brazilian market.

Biomm is Brazil’s first and only biotechnology focused company, providing high quality healthcare to patients with chronic conditions and enhancing access to the latest technologies and treatments. The Company focuses on developing, manufacturing and commercializing complex biotech and biosimilar drug products at their state-of-the-art production facility in Nova Lima.

Biocon is India’s largest and Asia’s leading Biotechnology Company with a strategic focus on biopharmaceuticals and research services. It is a fully integrated, innovation driven biopharma enterprise offering affordable solutions for chronic diseases to patient's worldwide.